CL2019002919A1 - Compuestos inhibidores vmat2 y composiciones relacionadas. - Google Patents
Compuestos inhibidores vmat2 y composiciones relacionadas.Info
- Publication number
- CL2019002919A1 CL2019002919A1 CL2019002919A CL2019002919A CL2019002919A1 CL 2019002919 A1 CL2019002919 A1 CL 2019002919A1 CL 2019002919 A CL2019002919 A CL 2019002919A CL 2019002919 A CL2019002919 A CL 2019002919A CL 2019002919 A1 CL2019002919 A1 CL 2019002919A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- inhibitory compounds
- related compositions
- vmat2
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 2
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 abstract 1
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487413P | 2017-04-19 | 2017-04-19 | |
| US201862652837P | 2018-04-04 | 2018-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019002919A1 true CL2019002919A1 (es) | 2020-01-17 |
Family
ID=62111264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002919A CL2019002919A1 (es) | 2017-04-19 | 2019-10-14 | Compuestos inhibidores vmat2 y composiciones relacionadas. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11040970B2 (enExample) |
| EP (1) | EP3612532B1 (enExample) |
| JP (1) | JP7170662B2 (enExample) |
| KR (1) | KR20190140968A (enExample) |
| CN (1) | CN110770236B (enExample) |
| AU (1) | AU2018254429A1 (enExample) |
| BR (1) | BR112019021853A2 (enExample) |
| CA (1) | CA3060251A1 (enExample) |
| CL (1) | CL2019002919A1 (enExample) |
| CO (1) | CO2019011604A2 (enExample) |
| ES (1) | ES2971230T3 (enExample) |
| JO (1) | JOP20190239A1 (enExample) |
| MA (1) | MA50145A (enExample) |
| MX (1) | MX2019012336A (enExample) |
| PE (1) | PE20191784A1 (enExample) |
| TW (1) | TW201841913A (enExample) |
| WO (1) | WO2018195121A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11866451B2 (en) | 2019-11-11 | 2024-01-09 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
| US12247038B2 (en) | 2019-09-30 | 2025-03-11 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230170136A (ko) | 2017-01-27 | 2023-12-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CA3076000A1 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| JOP20200298A1 (ar) * | 2018-06-14 | 2020-11-22 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| WO2020086765A1 (en) * | 2018-10-24 | 2020-04-30 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| PE20240822A1 (es) | 2021-03-22 | 2024-04-18 | Neurocrine Biosciences Inc | Inhibidores de vmat2 y metodos de uso |
| WO2022232380A1 (en) | 2021-04-29 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| CA3229341A1 (en) | 2021-08-20 | 2023-02-23 | Ryan TERRY-LORENZO | Methods of screening for vmat2 inhibitors |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| ATE437876T1 (de) | 2003-06-20 | 2009-08-15 | Hoffmann La Roche | Hexahydropyridoisochinoline als dpp-iv- inhibitoren |
| JP2008509925A (ja) * | 2004-08-13 | 2008-04-03 | オメロス コーポレイション | 新規のセロトニンレセプターリガンドおよびそれらの使用 |
| DK2081929T3 (da) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
| FR2912145B1 (fr) | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US9012471B2 (en) * | 2008-04-11 | 2015-04-21 | The Trustees Of Columbia University In The City Of New York | Glucose metabolism modulating compounds |
| NZ591615A (en) | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2784830C (en) * | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| WO2014043866A1 (zh) | 2012-09-19 | 2014-03-27 | 中国科学院福建物质结构研究所 | 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途 |
| US9782398B2 (en) | 2014-02-07 | 2017-10-10 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof |
| KR102586138B1 (ko) | 2015-02-06 | 2023-10-05 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | [9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법 |
| US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP4223369A1 (en) | 2016-12-22 | 2023-08-09 | Incyte Corporation | Immunomodulator compounds and methods of use |
-
2017
- 2017-06-16 JO JOP/2019/0239A patent/JOP20190239A1/ar unknown
-
2018
- 2018-04-17 PE PE2019002077A patent/PE20191784A1/es unknown
- 2018-04-17 CN CN201880040884.XA patent/CN110770236B/zh active Active
- 2018-04-17 TW TW107112964A patent/TW201841913A/zh unknown
- 2018-04-17 JP JP2019556587A patent/JP7170662B2/ja active Active
- 2018-04-17 WO PCT/US2018/028031 patent/WO2018195121A1/en not_active Ceased
- 2018-04-17 MX MX2019012336A patent/MX2019012336A/es unknown
- 2018-04-17 EP EP18722357.3A patent/EP3612532B1/en active Active
- 2018-04-17 KR KR1020197033620A patent/KR20190140968A/ko not_active Withdrawn
- 2018-04-17 US US16/606,191 patent/US11040970B2/en active Active
- 2018-04-17 ES ES18722357T patent/ES2971230T3/es active Active
- 2018-04-17 CA CA3060251A patent/CA3060251A1/en active Pending
- 2018-04-17 AU AU2018254429A patent/AU2018254429A1/en not_active Abandoned
- 2018-04-17 BR BR112019021853-0A patent/BR112019021853A2/pt not_active Application Discontinuation
- 2018-04-17 MA MA050145A patent/MA50145A/fr unknown
-
2019
- 2019-10-14 CL CL2019002919A patent/CL2019002919A1/es unknown
- 2019-10-18 CO CO2019011604A patent/CO2019011604A2/es unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247038B2 (en) | 2019-09-30 | 2025-03-11 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| US11866451B2 (en) | 2019-11-11 | 2024-01-09 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7170662B2 (ja) | 2022-11-14 |
| US11040970B2 (en) | 2021-06-22 |
| CN110770236B (zh) | 2023-03-24 |
| MX2019012336A (es) | 2020-07-14 |
| PE20191784A1 (es) | 2019-12-24 |
| KR20190140968A (ko) | 2019-12-20 |
| AU2018254429A1 (en) | 2019-11-07 |
| EP3612532B1 (en) | 2023-12-13 |
| EP3612532A1 (en) | 2020-02-26 |
| MA50145A (fr) | 2020-07-29 |
| EP3612532C0 (en) | 2023-12-13 |
| WO2018195121A1 (en) | 2018-10-25 |
| BR112019021853A2 (pt) | 2020-05-26 |
| TW201841913A (zh) | 2018-12-01 |
| CO2019011604A2 (es) | 2019-10-31 |
| CN110770236A (zh) | 2020-02-07 |
| CA3060251A1 (en) | 2018-10-25 |
| JP2020517607A (ja) | 2020-06-18 |
| JOP20190239A1 (ar) | 2019-10-09 |
| US20200131173A1 (en) | 2020-04-30 |
| ES2971230T3 (es) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011604A2 (es) | Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
| CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
| CL2019000368A1 (es) | Inhibidores de cdk2/4/6. | |
| MX2020000261A (es) | Nuevos compuestos. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| MX2017010062A (es) | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. | |
| MX390698B (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| MY177574A (en) | New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
| CL2019001495A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih. | |
| CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| UY34530A (es) | Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1) | |
| UY32180A (es) | Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1) | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| ECSP109958A (es) | Derivados de pirimidina 934 | |
| MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
| MX2017009824A (es) | Triazoles sustituidos y metodos relacionados a estos. | |
| MX2020001157A (es) | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). | |
| CO2020016080A2 (es) | Compuestos | |
| AR104731A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| ECSP21011232A (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
| CU24550B1 (es) | Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos |